Los Angeles Capital Management LLC Neurocrine Biosciences Inc Transaction History

Los Angeles Capital Management LLC

$22.3 Billion
Q1 2025

A detailed history of Los Angeles Capital Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 3,808 shares of NBIX stock, worth $457,645. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,808

Previous 512,820 99.26%

Holding current value

$457,645

Previous $70 Million 99.4%

% of portfolio

0.0%

Previous 0.29%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 05, 2025	SELL	$107.22 - $153.29 $54.6 Million - $78 Million	-509,012 Reduced 99.26%	3,808 $421,000
Q4 2024 Feb 04, 2025	BUY	$111.62 - $139.44 $10.3 Million - $12.8 Million	92,072 Added 21.88%	512,820 $70 Million
Q3 2024 Nov 04, 2024	BUY	$114.58 - $153.15 $41.7 Million - $55.7 Million	363,863 Added 639.65%	420,748 $48.4 Million
Q2 2024 Aug 05, 2024	SELL	$130.86 - $143.19 $24.7 Million - $27 Million	-188,496 Reduced 76.82%	56,885 $7.83 Million
Q1 2024 Apr 05, 2024	SELL	$130.4 - $143.74 $87.8 Million - $96.7 Million	-673,010 Reduced 73.28%	245,381 $33.8 Million
Q4 2023 Feb 06, 2024	BUY	$106.07 - $132.76 $38.7 Million - $48.5 Million	364,986 Added 65.95%	918,391 $121 Million
Q3 2023 Nov 06, 2023	BUY	$94.02 - $117.1 $263,914 - $328,699	2,807 Added 0.51%	553,405 $62.3 Million
Q2 2023 Aug 03, 2023	SELL	$89.53 - $104.87 $7.54 Million - $8.83 Million	-84,247 Reduced 13.27%	550,598 $51.9 Million
Q1 2023 May 04, 2023	SELL	$94.11 - $123.02 $12.1 Million - $15.9 Million	-128,847 Reduced 16.87%	634,845 $64.3 Million
Q4 2022 Feb 06, 2023	SELL	$106.72 - $127.06 $3.02 Million - $3.59 Million	-28,274 Reduced 3.57%	763,692 $91.2 Million
Q3 2022 Nov 02, 2022	BUY	$92.03 - $107.81 $72.9 Million - $85.4 Million	791,966 New	791,966 $84.1 Million
Q4 2021 Feb 03, 2022	SELL	$79.65 - $106.22 $1.12 Million - $1.49 Million	-14,016 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$86.18 - $99.03 $446,153 - $512,678	-5,177 Reduced 26.97%	14,016 $1.34 Million
Q2 2021 Aug 05, 2021	SELL	$89.43 - $102.27 $3.24 Million - $3.71 Million	-36,255 Reduced 65.39%	19,193 $1.87 Million
Q1 2021 May 05, 2021	SELL	$87.57 - $119.4 $7.9 Million - $10.8 Million	-90,189 Reduced 61.93%	55,448 $5.39 Million
Q4 2020 Feb 04, 2021	SELL	$86.91 - $108.33 $2.7 Million - $3.37 Million	-31,120 Reduced 17.61%	145,637 $14 Million
Q3 2020 Nov 02, 2020	BUY	$96.16 - $135.15 $4.2 Million - $5.9 Million	43,631 Added 32.77%	176,757 $17 Million
Q2 2020 Aug 05, 2020	BUY	$85.09 - $130.36 $10.4 Million - $16 Million	122,431 Added 1144.75%	133,126 $16.2 Million
Q1 2020 May 04, 2020	BUY	$75.11 - $113.76 $179,888 - $272,455	2,395 Added 28.86%	10,695 $926,000
Q4 2019 Feb 07, 2020	BUY	$86.8 - $118.57 $410,564 - $560,836	4,730 Added 132.49%	8,300 $892,000
Q3 2019 Nov 07, 2019	SELL	$83.82 - $101.5 $1.21 Million - $1.46 Million	-14,380 Reduced 80.11%	3,570 $322,000
Q2 2019 Jul 29, 2019	SELL	$72.24 - $91.27 $510,014 - $644,366	-7,060 Reduced 28.23%	17,950 $1.52 Million
Q1 2019 Apr 25, 2019	BUY	$69.31 - $91.53 $1.46 Million - $1.93 Million	21,040 Added 529.97%	25,010 $2.2 Million
Q4 2018 Feb 11, 2019	BUY	$68.32 - $124.36 $128,441 - $233,796	1,880 Added 89.95%	3,970 $283,000
Q3 2018 Nov 05, 2018	SELL	$98.88 - $125.85 $353,001 - $449,284	-3,570 Reduced 63.07%	2,090 $257,000
Q2 2018 Jul 31, 2018	SELL	$75.3 - $105.99 $181,473 - $255,435	-2,410 Reduced 29.86%	5,660 $556,000
Q1 2018 Apr 27, 2018	BUY	$75.88 - $92.43 $612,351 - $745,910	8,070 New	8,070 $669,000

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

97.2M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.

Account

Los Angeles Capital Management LLC Neurocrine Biosciences Inc Transaction History